cbdMD Announces Publication of Human Clinical Trial Data
cbdMD (NYSE: YCBD) announced the publication of its human clinical trial data in the Journal of the International Society of Sports Nutrition. The study, conducted by the University of South Carolina, evaluated the effects of daily intake of 100 mg of cbdMD's Broad Spectrum CBD blend over 12 weeks on healthy adults.
Key findings include significant pain reduction, improved psychological well-being in male participants, and reduced perceived stress in female participants. The study confirmed the safety and tolerability of the product, aligning with previous research on safe CBD consumption levels.
cbdMD highlighted the trial as evidence of their commitment to science, safety, and efficacy, reinforcing their leadership in the CBD industry.
- Significant pain reduction observed in trial participants after 90 days of consuming 100 mg of cbdMD's Broad Spectrum CBD blend.
- Improved psychological well-being in male subjects, with notable reductions in 'anger-hostility' scores after 60 days.
- Decreased perceived stress levels reported by female subjects over the 90-day period.
- Confirmation of the safety and tolerability of cbdMD's Broad Spectrum CBD blend, supporting previous research on safe consumption levels.
- None.
Insights
The publication of human clinical trial data on cbdMD's Broad Spectrum CBD blend is a significant development for the company and its stakeholders. The trial's design as a randomized, double-blind, placebo-controlled study enhances its credibility, providing a high level of evidence on the efficacy and safety of the product.
The study’s findings of
Importantly, the confirmation of the product’s safety aligns with previous toxicity research, supporting long-term use. This safety profile is important for retaining consumer trust and meeting regulatory requirements. Furthermore, publishing in a reputable journal like the Journal of the International Society of Sports Nutrition adds to the legitimacy of the results.
However, it is essential to consider the study’s limitations, such as the relatively small sample size and specific focus on a healthy adult population, which may not fully represent broader consumer demographics. Nonetheless, this data positions cbdMD favorably within the competitive CBD market.
Overall, these findings should bolster investor confidence in cbdMD’s commitment to rigorous scientific validation, providing a solid foundation for future market expansion and product development.
The release of these clinical trial results is likely to create positive momentum for cbdMD on the business front. The documented efficacy and safety of the Broad Spectrum CBD blend can drive product differentiation in an increasingly saturated CBD market, where consumers are often skeptical about the legitimacy and effectiveness of various offerings. This can translate into increased brand loyalty and sales growth.
The focus on pain relief and mental well-being is particularly strategic. These areas are high-priority concerns for many consumers and have substantial market potential. According to industry reports, the global pain management market is expected to reach
Moreover, the publication of these findings in a respected journal enhances cbdMD’s brand credibility, which can be leveraged in marketing and promotional activities. It also sets a benchmark for competitors, potentially positioning cbdMD as a leader in scientifically backed CBD products. This differentiation can be a important factor in market growth, investor confidence and long-term competitiveness.
However, the company must continue to invest in further research and development to expand its product efficacy claims across other demographics and conditions to maintain this competitive edge.
Charlotte, North Carolina--(Newsfile Corp. - June 27, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company"), one of the nation's leading providers of premium cannabidiol (CBD) products, today announced the publication of the Company's human clinical trial data demonstrating the benefits of its proprietary Broad Spectrum CBD blend. The data was published in the Journal of the International Society of Sports Nutrition.
The randomized, double-blind, placebo-controlled trial was completed by researchers at the University of South Carolina to investigate the benefits of daily intake of 100 mg of the Company's Broad Spectrum CBD blend on its potential anti-inflammatory, immunomodulatory, psychological, and pain-relieving effects in healthy adults over a 12-week period. Key findings include:
- Significant Pain Reduction: Participants consuming 100 mg of cbdMD's Broad Spectrum CBD blend daily for 90 days experienced substantial pain relief compared to the placebo group.
- Improved Psychological Well-being: Male subjects showed notable reductions in "anger-hostility" scores after 60 days of consumption.
- Stress Reduction: Female subjects reported decreased perceived stress levels over the 90-day period of consumption.
Importantly, the study confirms that cbdMD's Broad Spectrum CBD is safe and well-tolerated, aligning with prior toxicity research that validates the safety of consuming 2.29 mg/kg of body weight daily.
A leader in the industry, cbdMD believes the publication of this human clinical data reinforces to its customers, stakeholders, and regulators, the Company's unwavering commitment to science, safety and efficacy. This builds upon the foundation of safety studies cbdMD has contributed to demonstrate the safe level of cannabidiol consumption for humans, underscoring the Company's continued role as a leader in the space.
"This paper is a prime example of cbdMD's approach to science, which has laid the foundation for cbdMD to deliver safe, effective products formulated to specifically address the needs of our customers. We have proven cbdMD's products are safe and now we are showing our customers our commitment to efficacy in crucial areas such as pain management. When you seek a trustworthy product backed by science, look no further than cbdMD." said Ronan Kennedy, CEO and CFO.
To view the complete published paper titled, "The effects of a brand-specific, hemp-derived cannabidiol product on physiological, biochemical, and psychometric outcomes in healthy adults: a double-blind, randomized clinical trial", please visit https://www.tandfonline.com/doi/full/10.1080/15502783.2024.2370430.
About cbdMD, Inc.:
cbdMD, Inc. is one of the leading and most highly trusted and most recognized Cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, including NSF Certified for Sport® products, as well as a wide array of Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids, and a growing collection of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures and chews in varying strengths, and our ATRx Labs brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, or ATRxLabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retailers nationwide that carry cbdMD's products.
1 THC-free is defined as below the level of detection using validated scientific analytical methods.
Forward-Looking Statements:
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to limited clinical data, , federal and state regulation of CBD products, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 as filed with the Securities and Exchange Commission (the "SEC") and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
Contact Information:
cbdMD, Inc.
Ronan Kennedy, CEO & CFO
+1 (704) 445-3064
IR@cbdmd.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/214644
FAQ
What were the key findings of cbdMD's clinical trial published on June 27, 2024?
What safety data about cbdMD's Broad Spectrum CBD blend was published in June 2024?
How did cbdMD's clinical trial affect male participants?
What stress-related results were observed in cbdMD's clinical trial for female participants?
What does the publication of cbdMD's clinical trial data signify for the company?
